Department of Radiopharmacy, Faculty of Pharmacy, Mazandaran University of Medical Sciences, Sari, Iran.
Curr Med Chem. 2022 Aug 11;29(29):4923-4957. doi: 10.2174/0929867329666220420131836.
A homomultimeric radioligand is composed of multiple identical ligands connected to the linker and radionuclide to detect a variety of overexpressed receptors on cancer cells. Multimer strategy holds great potential for introducing new radiotracers based on peptide and monoclonal antibody (mAb) derivatives in molecular imaging and therapy. It offers a reliable procedure for the preparation of biological-based targeting with diverse affinities and pharmacokinetics. In this context, we provide a useful summary and interpretation of the main results by a comprehensive look at multimeric radiopharmaceuticals in nuclear oncology. Therefore, explanations for the strategy mechanisms and the main variables affecting the biodistribution results will be explained. The discussion is followed by highlights of recent work in the targeting of various types of receptors. The consequences are expressed based on comparing some parameters between monomer and multimer counterparts in each relevant section.
一种同型多聚体放射性配体由多个连接到接头和放射性核素上的相同配体组成,用于检测癌细胞上各种过表达的受体。多聚体策略在基于肽和单克隆抗体 (mAb) 衍生物的分子成像和治疗中为引入新的放射性示踪剂提供了巨大的潜力。它为制备具有不同亲和力和药代动力学的基于生物的靶向提供了可靠的程序。在这方面,我们通过全面考察核肿瘤学中的多聚体放射性药物,对主要结果进行了有用的总结和解释。因此,将解释该策略的机制以及影响生物分布结果的主要变量。讨论之后,重点介绍了针对各种类型受体的最新工作。结果是基于在每个相关部分中比较单体和多聚体对应物的一些参数得出的。